Population Pharmacokinetic and Exposure-Response Modeling Supports BI 764198 20 mg as the Therapeutic Dose for Phase 3, with No Dose Adjustment Required

BI 764198 - Boehringer Ingelheim, Aurobac Therapeutics

https://www.asn-online.org/education/kidneyweek/2025/program-abstract.aspx?controlId=4396513

Silke Retlich; Hendrik Maxime Lagraauw; Klas Jf Petersson; Undine Falkenhagen; Alexander Voelkner; Nima Soleymanlou; Maximilian T Lobmeyer; Srinivasa Prasad; Howard Trachtman; Lisa Bungert

Oct 18, 2025